drugset / Trial / NCT02046564
Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and the safety of ASC-01 (aripiprazole/sertraline combination) compared to sertraline monotherapy in patients with major depressive disorders who have responded incompletely to sertraline monotherapy.
Timeline
- Start
- 2014-02
- Primary completion
- 2016-09
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 3 mg | Oral |
| Subject | Aripiprazole | Other / unclassified | 12 mg | Oral |
| Background | Sertraline | Small molecule | 100 mg | Oral |